Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin‐resistant obese mice

Over the last decades polyetiological metabolic diseases such as obesity and type 2 diabetes have emerged as a global epidemic. Efficient strategies for prevention and treatment include dietary intervention and the development of validated nutraceuticals. Safe extracts of edible plants provide a resource of structurally diverse molecules that can effectively interfere with multifactorial diseases. In this study, we describe the application of ethanolic lemon balm ( Melissa officinalis ) leaves extract for the treatment of insulin‐resistance and dyslipidemia in mice. We show that lemon balm extract ( LBE ) activates the peroxisome proliferator‐activated receptors ( PPAR s), which have key roles in the regulation of whole body glucose and lipid metabolism. Application of LBE (0.6 mg/mL) to human primary adipocytes resulted in specific peroxisome proliferator‐activated receptor target gene expression. LBE treatment of insulin‐resistant high‐fat diet‐fed C 57 BL /6 mice (200 mg/kg/day) for 6 weeks considerably reduced hyperglycemia and insulin resistance, plasma triacylglycerol, nonesterified fatty acids and LDL/VLDL cholesterol levels. Taken together, ethanolic lemon balm extract can potentially be used to prevent or concomitantly treat type 2 diabetes and associated disorders such as dyslipidemia and hypercholesterolemia.